> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pacira Must Pay Exparel Royalties On Its Larger-Scale Process After Partial Court Reversal
- URL: https://www.bullished.co/pacira-must-pay-exparel-royalties-on-its-larger-scale-process-after-partial-court-reversal-409ae4a6/
- Published: 2026-11-12T21:42:09.000Z
- Updated: 2026-11-12T21:42:09.000Z
- Description: The dispute concerns its biggest product and a judgment that brought Pacira $28.3 million in repayment and interest.
- Author: Matteo Parrino
- Tags: SEC Filings, PCRX, Industry: Healthcare

[Pacira BioSciences](https://www.bullished.co/tag/pcrx/), which develops and sells non-opioid pain treatments, lost part of its court victory Friday when the Ninth Circuit ruled that it [owes Exparel royalties](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126043437/ef20085356%5F8k.htm?ref=bullished.co) on its 200-liter manufacturing process. Pacira described the ruling in an SEC filing Thursday; the decision revisits a dispute in which it received $28.3 million in repayment and interest.

## Royalties Return On The 200-Liter Process

The appeals court directed the U.S. District Court for the District of Nevada to rule for Research Development Foundation, Pacira's patent-rights counterparty, on the larger-scale manufacturing claim. It also sent back the portion concerning Exparel made in 45-liter batches so the district court can recalculate interest the foundation owes Pacira.

The agreement required Pacira to pay royalties of a few percent on revenue from certain products while assigned patents remained valid. The foundation can terminate the agreement over an uncured material breach, Pacira's bankruptcy or insolvency, or a challenge by Pacira to those patent rights.

Exparel is central to Pacira's business: its [2025 net sales](https://news.bloomberglaw.com/ip-law/pacira-required-to-pay-patent-owner-royalties-on-exparel-sales?ref=bullished.co) were $575.1 million, accounting for 79% of total revenue. The long-acting local anesthetic injection is approved for postsurgical pain.

Pacira's other commercial products are Zilretta, an extended-release steroid injection for osteoarthritis knee pain, and iovera, a handheld device that relieves pain by applying cold to a targeted nerve. They generated $116.6 million and $24.2 million in 2025 sales, respectively. The Brisbane, California-based company is also developing PCRX-201, a gene therapy in mid-stage trials for knee osteoarthritis.

## A Repayment Victory Faces Revision

Pacira maintains that its royalty obligations ended on December 24, 2021, when an assigned patent expired. The foundation argues that another patent, issued on June 15, 2021, extended payments until 2041.

Pacira sued in December 2021, asking the Nevada district court to declare that it owed no Exparel royalties after the expiration date. In August 2023, it won a ruling ending royalties on the 45-liter process. The larger-scale process went to trial in September 2024, and Pacira won that claim in April 2025.

Those victories eliminated the disputed royalty, and Pacira sought recovery of up to $23.1 million plus interest for payments made under protest. A June 2025 judgment awarded the $23.1 million repayment and $5.2 million in statutory interest. Pacira [received $28.3 million](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126043437/ef20085356%5F8k.htm?ref=bullished.co) in cash in July 2025.

The foundation filed notices of appeal in May and September 2025\. Friday's decision partially reversed the district court's judgment, restoring the payment obligation for the 200-liter process while requiring another calculation of interest for the 45-liter portion.

Pacira is evaluating its legal options and intends to defend its rights. The company cautioned that it cannot predict the outcome of the case.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Pacira BioSciences, Inc. (PCRX)](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126043437/ef20085356%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Pacira Required to Pay Patent Owner Royalties on Exparel Sales](https://news.bloomberglaw.com/ip-law/pacira-required-to-pay-patent-owner-royalties-on-exparel-sales?ref=bullished.co) — news.bloomberglaw.com

### More on Pacira BioSciences

- [Pacira Withdraws 2026 Guidance And Skips Earnings Call While Viatris' $36.50 Offer Runs](https://www.bullished.co/pacira-withdraws-2026-guidance-and-skips-earnings-call-while-viatris-36-50-offer-runs-781a55b2/)
- [Pacira Board Urges Holders To Take Viatris's $36.50 Cash, Up From $31.00 Opening Bid](https://www.bullished.co/pacira-board-urges-holders-to-take-viatriss-36-50-cash-up-from-31-00-opening-bid-43664943/)
- [Viatris Starts $36.50-A-Share Cash Tender Offer For Pacira, A Few Cents Above Its Last Close](https://www.bullished.co/viatris-starts-36-50-a-share-cash-tender-offer-for-pacira-a-few-cents-above-its-last-close-68747ece/)

[All Pacira BioSciences (PCRX) coverage →](https://www.bullished.co/tag/pcrx/)